• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patient in the high dose cohort of its Phase 1b study (E011-MEL) of ECI-006 as an adjuvant therapy in metastatic melanoma patients.

The high dose cohort (1800 µg) of the E011-MEL study aims to recruit ten patients, at centers in Belgium and Spain, who will receive five injections of ECI-006 administered intranodally over a period of 14 weeks.

eTheRNA to present at Bio€quity Europe

Niel (Belgium), 14 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that Acting CEO Marc Dechamps will present at Bio€quity Europe, which takes place from 14-16 May in Ghent, Belgium.

The presentation will provide an overview of the Company as well as ongoing and planned clinical trials for the development of its directly injectable formulations of cancer immunotherapies based on its innovative mRNA TriMix platform. Details for the presentation are as follows:

Date: Tuesday 15 May 2018
Time: 16:40-17:00
Location: Level 1+, Priorzaal, Het Pand, Ghent University

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

ECI-006 is safe and well tolerated

Niel (Belgium), 19 March 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose cohort in its Phase 1b study (E011-MEL) of ECI-006 as an adjuvant therapy in metastatic melanoma patients.

Ten patients in total have been recruited for the low dose cohort (600 µg) and all patients have received at least four doses. A total of 44 doses have been administered with no adverse safety signals. Intranodal administration was associated with a 100% compliance.